Abstract
Purpose :
To evaluate the value of IHC staining for BAP1 and PRAME in a routine clinical setup
Methods :
Patients treated for uveal melanoma from 2017 to 2021 were included in the study. IHC stainings were performed on both cytospin, enucleated eyes and cell blocks using self-clotting technique
Results :
A total of 222 patients were diagnosed with uveal melanoma at the Copenhagen University clinic. 143 patients were treated for Choroidal melanoma, 13 for ciliary body melanoma and 66 for iris melanoma. One patient with iris melanoma chose not to be operated.One Patient was treated for bilateral uveal. melanoma.Of the 65 Patients with iris melanoma 64 were treated with local resection and one patient was enucleated. Of the 156 patients with posterior melanoma, 45 had TransVitreal-RetinoChoroidal biopsy (TVRC) followed by enucleation of the eye and.4 patients had only enucleation. A total of 103 patients with posterior melanoma had TVRC and Brachytherapy and 1 patients was only treated with brachytherapy..
55 of 65 Iris patients had BAP1 IHC performed.. One patient had too little material for analyses and one sample was inconclusive, leaving 53 (96%) sample diagnostic. 47 of 49 enucleates eyes were analysed for BAP! IHC and only 1 was inconclusive leaving a total of 46 samples diagnostic (98%). For the TVRC this number was only 55% (73 of 133 patients)
Conclusions :
BAP1 IHC yields a high outcome when "true" histology is availble, but is not very stable in cytological preparations.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.